Equitable Holdings Inc. Makes New Investment in Pfizer Inc. $PFE

Key Points

• Equitable Holdings purchased 203,198 Pfizer shares in the second quarter, valued at approximately $4.9 million. Institutional investors and hedge funds collectively own 68.36% of Pfizer.
• Pfizer reported quarterly earnings of $0.77 per share, beating estimates of $0.68, while revenue rose 2.6% year over year to $15.03 billion. The company maintained 2026 earnings guidance of $2.80–$3.00 per share.
• The FDA approved Pfizer and BioNTech’s updated 2026–2027 COVID-19 vaccine, potentially supporting seasonal revenue. Pfizer also declared a quarterly dividend of $0.43 per share, representing a 6.1% annualized yield, though its payout ratio remains elevated.

Equitable Holdings Inc. purchased a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 203,198 shares of the biopharmaceutical company's stock, valued at approximately $4,893,000.

Several other hedge funds also recently made changes to their positions in the business. Evolution Wealth Management Inc. grew its position in Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 566 shares during the last quarter. Godfrey Financial Associates Inc. acquired a new position in shares of Pfizer in the 4th quarter worth $26,000. Keb Asset Management LLC acquired a new stake in shares of Pfizer during the second quarter worth $26,000. HFM Investment Advisors LLC raised its position in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 427 shares during the period. Finally, Global Trust Asset Management LLC lifted its holdings in shares of Pfizer by 126.7% during the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 650 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COVID-19 vaccine. The updated Comirnaty formula is intended for adults 65 and older and younger individuals with qualifying health risks, with shipments beginning immediately. The approval supports Pfizer’s ability to compete in the upcoming respiratory-virus season and could provide seasonal revenue support. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
• Positive Sentiment: The FDA also approved updated COVID-19 vaccines from Moderna and Novavax-Sanofi, following guidance to target the dominant XFG variant. Pfizer’s immediate distribution and extensive real-world safety record may help preserve its position in the U.S. vaccine market, although demand remains difficult to forecast. US FDA approves updated COVID vaccines for 2026-27 season

Pfizer Stock Performance

PFE stock opened at $28.00 on Friday. The firm has a 50 day simple moving average of $25.49 and a 200 day simple moving average of $26.29. Pfizer Inc. has a 52 week low of $23.58 and a 52 week high of $28.75. The stock has a market cap of $159.62 billion, a P/E ratio of 36.85 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the business earned $0.78 EPS. The company's revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. Pfizer's dividend payout ratio is 226.32%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Guggenheim dropped their price target on Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a research note on Friday, August 7th. Weiss Ratings lowered shares of Pfizer from a "hold (c)" rating to a "hold (c-)" rating in a research note on Monday, August 17th. Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Bank of America dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research report on Friday, July 10th. Finally, Wolfe Research restated an "underperform" rating and issued a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $28.28.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source